FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

An FDA advisory panel backed the safety of Grail's blood-based cancer detection test, Galleri, but was divided over evidence of its effectiveness. The mixed expert feedback creates uncertainty around the test's regulatory pathway and commercial prospects.